Astrocytoma Clinical Trial
— BNLOfficial title:
The Neural Basis of Language: A New Lighting. Study of Semantic Processing in MRI Mutimodale and Direct Electrical Stimulation
NCT number | NCT02903784 |
Other study ID # | 8674 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | September 2012 |
Est. completion date | September 2016 |
Verified date | May 2011 |
Source | University Hospital, Montpellier |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
According to the O.M.S. Classification, grade 2 glioma is a pre-cancerous lesion, slowly
progressive, infiltrating the central nervous system, mainly affecting young adults.
This surgery should nevertheless be conducted in awake condition to achieve two conflicting
goals: get maximum brain tissue infiltrated by the tumor while preserving the integrity of
functional structures. So awake after opening the skull, the patient undergoes a series of
preoperative tests, administered by a speech therapist present in the operating room. This
procedure allows the neurosurgeon to establish an individual functional brain mapping in real
time, through the observation by the SLP of the patient's answers to direct electrical
stimulation applied to the cortical and sub-cortical. This support is based on the
extraordinary plasticity demonstrated by the brain in the presence of a slowly progressive
lesion. To ensure the patient the highest achievable load should increase our understanding
of brain function, including the neural bases of language, glioma grade 2 is predominantly
localized functional area of language.
Status | Completed |
Enrollment | 63 |
Est. completion date | September 2016 |
Est. primary completion date | February 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: Patients carry a grade glioma 2 functional area of language and presenting the information to receive surgical care provided in awake for the first time. or Healthy volunteers will be selected using a matching age and sex of patients in the study (matched to a patient on two of the first forty patients). Exclusion Criteria: - Subject presenting cons-indications to MRI (ventricular shunt valve, ferromagnetic foreign bodies, pacemaker, implantable defibrillators, cochlear hearing implant, claustrophobia, ....) - History of head trauma, ischemic stroke or intracerebral hematoma. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | functional score | The intraoperative testing is performed by an evaluator (speech / neuropsychologist), present in the operating room, the patient's side. Its role is to identify functional disturbances induced by direct electrical stimulation. To do this, two standardized tests are administered to the patient alternately for the duration of the awake period. These tests are presented on a computer screen in PowerPoint format, with a picture every four seconds. |
1 day | |
Secondary | Evaluation orthophonic | Spontaneous Speech Test oral denomination: DO. 80 with computerized measurement of reaction time Verbal Fluence Categorical: animals Formal: letter / p / Test semantic matching: PPTT with computerized measurement of the reaction time trial test semantics / phonology Image Designation |
1 day | |
Secondary | Evaluation orthophonic | Spontaneous Speech Test oral denomination: DO. 80 with computerized measurement of reaction time Verbal Fluence Categorical: animals Formal: letter / p / Test semantic matching: PPTT with computerized measurement of the reaction time trial test semantics / phonology Image Designation |
5 day | |
Secondary | Evaluation orthophonic | Spontaneous Speech Test oral denomination: DO. 80 with computerized measurement of reaction time Verbal Fluence Categorical: animals Formal: letter / p / Test semantic matching: PPTT with computerized measurement of the reaction time trial test semantics / phonology Image Designation |
3 month | |
Secondary | Imagery Data | Imagery Data | 1 day | |
Secondary | Imagery Data | Imagery Data | 5 day | |
Secondary | Imagery Data | Imagery Data | 6 month |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02764151 -
First in Patient Study for PF-06840003 in Malignant Gliomas
|
Phase 1 | |
Completed |
NCT00994071 -
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
|
Phase 1 | |
Terminated |
NCT01502605 -
Phase I Study of Orally Administered Aminolevulinic Acid for Resection of Malignant Astrocytomas
|
Phase 1 | |
Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Completed |
NCT00705198 -
Temozolomide All-Case-Registered Surveillance (Designated Drug Use Investigation)(Study P05062)
|
N/A | |
Completed |
NCT00165360 -
Prolonged Daily Temozolomide for Low-Grade Glioma
|
Phase 2 | |
Active, not recruiting |
NCT03911388 -
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
|
Phase 1 | |
Terminated |
NCT00389090 -
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
|
Phase 2 | |
Completed |
NCT00154375 -
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
|
Phase 3 | |
Completed |
NCT00001148 -
Detecting Malignant Brain Tumor Cells in the Bloodstream During Surgery to Remove the Tumor
|
N/A | |
Completed |
NCT03722355 -
Hyperfractionated RT With BCNU Versus Conventional RT With BCNU for Supratentorial Malignant Glioma
|
Phase 3 | |
Recruiting |
NCT03975829 -
Pediatric Long-Term Follow-up and Rollover Study
|
Phase 4 | |
Recruiting |
NCT05686798 -
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
|
Phase 1 | |
Active, not recruiting |
NCT03739372 -
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma
|
N/A | |
Recruiting |
NCT05624736 -
Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
|
||
Recruiting |
NCT05345002 -
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
|
Phase 2 | |
Recruiting |
NCT04028479 -
The Registry of Oncology Outcomes Associated With Testing and Treatment
|
||
Completed |
NCT00783393 -
SCH 52365 Phase II Clinical Study: A Study on the Efficacy and Safety of Monotherapy With SCH 52365 in Patients With First Relapsed Anaplastic Astrocytoma (Study P03745)
|
Phase 2 | |
Completed |
NCT03900689 -
Social Determinants of Health in Glioblastoma Population
|
||
Completed |
NCT02747407 -
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
|